Quidel Corporation (NASDAQ:QDEL) SVP Ratan S. Borkar sold 7,965 shares of Quidel Corporation stock in a transaction dated Thursday, November 9th. The stock was sold at an average price of $38.91, for a total transaction of $309,918.15. Following the sale, the senior vice president now directly owns 11,084 shares of the company’s stock, valued at approximately $431,278.44. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Shares of Quidel Corporation (NASDAQ:QDEL) opened at $38.18 on Tuesday. Quidel Corporation has a twelve month low of $18.25 and a twelve month high of $45.55. The company has a current ratio of 6.28, a quick ratio of 5.68 and a debt-to-equity ratio of 0.70.
Quidel Corporation (NASDAQ:QDEL) last released its quarterly earnings data on Wednesday, November 1st. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.05 by ($0.21). The company had revenue of $50.89 million for the quarter, compared to analyst estimates of $50.47 million. Quidel Corporation had a negative return on equity of 2.36% and a negative net margin of 2.33%. Quidel Corporation’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.10 earnings per share. sell-side analysts expect that Quidel Corporation will post 0.6 earnings per share for the current fiscal year.
QDEL has been the subject of a number of recent research reports. Zacks Investment Research raised shares of Quidel Corporation from a “hold” rating to a “buy” rating and set a $30.00 price objective for the company in a report on Tuesday, July 18th. Canaccord Genuity raised shares of Quidel Corporation from a “hold” rating to a “buy” rating in a report on Tuesday, July 18th. William Blair raised shares of Quidel Corporation from a “market perform” rating to an “outperform” rating in a report on Tuesday, July 18th. Barclays PLC boosted their price objective on shares of Quidel Corporation from $36.00 to $39.00 and gave the company an “overweight” rating in a report on Thursday, July 27th. Finally, Raymond James Financial, Inc. boosted their price objective on shares of Quidel Corporation from $36.00 to $41.00 and gave the company an “outperform” rating in a report on Thursday, July 27th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $48.80.
About Quidel Corporation
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.
Receive News & Ratings for Quidel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel Corporation and related companies with MarketBeat.com's FREE daily email newsletter.